SGLT-2 inhibitors reduce non-fatal myocardial infarction (odds ratio 0.90, 95% confidence interval 0.82 to 0.98; high certainty)—as, probably, do GLP-1 receptor agonists (0.91, 0.85 to 0.98; moderate certainty) and, possibly, metformin (0.86, 0.68 to 1.09; low certainty). This evidence concerns the gene GLP1R and myocardial infarction.